{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:47:44Z","timestamp":1784868464720,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Amryt Pharmaceuticals DAC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3362-z","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T13:03:42Z","timestamp":1560258222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Oleogel-S10 Phase 3 study \u201cEASE\u201d for epidermolysis bullosa: study design and rationale"],"prefix":"10.1186","volume":"20","author":[{"given":"Johannes S.","family":"Kern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Schwieger-Briel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"L\u00f6we","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sumeray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"key":"3362_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1172-5-12","volume":"5","author":"JD Fine","year":"2010","unstructured":"Fine JD. Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010;5:12. \n                    https:\/\/doi.org\/10.1186\/1750-1172-5-12\n                    \n                  .","journal-title":"Orphanet J Rare Dis"},{"key":"3362_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/sj.mt.6300041","volume":"15","author":"DT Woodley","year":"2007","unstructured":"Woodley DT, Remington J, Huang Y, Hou Y, Li W, Keene DR, et al. Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther. 2007;15:628\u201335. \n                    https:\/\/doi.org\/10.1038\/sj.mt.6300041\n                    \n                  .","journal-title":"Mol Ther"},{"key":"3362_CR3","unstructured":"European Medicines Agency. Episalvan EPAR; 2015. \n                    https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/episalvan\n                    \n                  ."},{"key":"3362_CR4","doi-asserted-by":"publisher","first-page":"e86147","DOI":"10.1371\/journal.pone.0086147","volume":"9","author":"S Ebeling","year":"2014","unstructured":"Ebeling S, Naumann K, Pollok S, Wardecki T, Vidal YSS, Nascimento JM, et al. From a traditional medicinal plant to a rational drug: understanding the clinically proven wound healing efficacy of birch bark extract. PLoS One. 2014;9:e86147. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0086147\n                    \n                  .","journal-title":"PLoS One"},{"key":"3362_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/jid.2009.248","volume":"130","author":"U Woelfle","year":"2010","unstructured":"Woelfle U, Laszczyk MN, Kraus M, Leuner K, Kersten A, Simon-Haarhaus B, et al. Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: a role for the transient receptor potential canonical (subtype) 6. J Invest Dermatol. 2010;130:113\u201323. \n                    https:\/\/doi.org\/10.1038\/jid.2009.248\n                    \n                  .","journal-title":"J Invest Dermatol"},{"key":"3362_CR6","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.3390\/toxins2102428","volume":"2","author":"VR Yadav","year":"2010","unstructured":"Yadav VR, Prasad S, Sung B, Kannappan R, Aggarwal BB. Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel). 2010;2:2428\u201366. \n                    https:\/\/doi.org\/10.3390\/toxins2102428\n                    \n                  .","journal-title":"Toxins (Basel)"},{"key":"3362_CR7","doi-asserted-by":"publisher","first-page":"5068969","DOI":"10.1155\/2017\/5068969","volume":"2017","author":"A Schwieger-Briel","year":"2017","unstructured":"Schwieger-Briel A, Kiritsi D, Schempp C, Has C, Schumann H. Betulin-based Oleogel to improve wound healing in dystrophic epidermolysis bullosa: a prospective controlled proof-of-concept study. Dermatol Res Pract. 2017;2017:5068969. \n                    https:\/\/doi.org\/10.1155\/2017\/5068969\n                    \n                  .","journal-title":"Dermatol Res Pract"},{"key":"3362_CR8","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.burns.2017.03.005","volume":"43","author":"JP Barret","year":"2017","unstructured":"Barret JP, Podmelle F, Lipovy B, Rennekampff HO, Schumann H, Schwieger-Briel A, et al. Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program. Burns. 2017;43:1284\u201394. \n                    https:\/\/doi.org\/10.1016\/j.burns.2017.03.005\n                    \n                  .","journal-title":"Burns"},{"key":"3362_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","volume":"70","author":"JD Fine","year":"2014","unstructured":"Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70:1103\u201326. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2014.01.903\n                    \n                  .","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3362_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.burns.2018.10.019","volume":"45","author":"Quentin Frew","year":"2019","unstructured":"Frew Q, Rennekampff HO, Dziewulski P, Moiemen N, BBW-11 Study Group, Zahn T, et al. Betulin wound gel accelerated healing of superficial partial thickness burns: Results of a randomized, intra-individually controlled, phase III trial with 12-months follow-up. Burns. 2018. \n                    https:\/\/doi.org\/10.1016\/j.burns.2018.10.019\n                    \n                  .","journal-title":"Burns"},{"key":"3362_CR11","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1055\/s-2006-951723","volume":"72","author":"M Laszczyk","year":"2006","unstructured":"Laszczyk M, Jager S, Simon-Haarhaus B, Scheffler A, Schempp CM. Physical, chemical and pharmacological characterization of a new oleogel-forming triterpene extract from the outer bark of birch (betulae cortex). Planta Med. 2006;72:1389\u201395. \n                    https:\/\/doi.org\/10.1055\/s-2006-951723\n                    \n                  .","journal-title":"Planta Med"},{"key":"3362_CR12","unstructured":"Denyer J, Pillay E, Clapham J. Best practice guidelines for skin and wound care in epidermolysis bullosa. An International Consensus. Wounds Int; 2017. \n                    https:\/\/www.wounds-uk.com\/resources\/all\/0\/date\/desc\/cont_type\/21\n                    \n                  ."},{"key":"3362_CR13","unstructured":"Food and Drug Administration. Guidance for Industry Chronic Cutaneous Ulcer and Burn Wounds \u2014 Developing Products for Treatment. Silver Spring: Food and Drug Administration; 2006."},{"key":"3362_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/pde.12317","volume":"32","author":"A Schwieger-Briel","year":"2015","unstructured":"Schwieger-Briel A, Chakkittakandiyil A, Lara-Corrales I, Aujla N, Lane AT, Lucky AW, et al. Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool. Pediatr Dermatol. 2015;32:41\u201352. \n                    https:\/\/doi.org\/10.1111\/pde.12317\n                    \n                  .","journal-title":"Pediatr Dermatol"},{"key":"3362_CR15","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","volume":"12","author":"AJ Scheen","year":"2010","unstructured":"Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12:648\u201358. \n                    https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01212.x\n                    \n                  .","journal-title":"Diabetes Obes Metab"},{"key":"3362_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/BCR.0b013e3182372bfa","volume":"33","author":"V Morris","year":"2012","unstructured":"Morris V, Murphy LM, Rosenberg M, Rosenberg L, Holzer CE 3rd, Meyer WJ 3rd. Itch assessment scale for the pediatric burn survivor. J Burn Care Res. 2012;33:419\u201324. \n                    https:\/\/doi.org\/10.1097\/BCR.0b013e3182372bfa\n                    \n                  .","journal-title":"J Burn Care Res"},{"key":"3362_CR17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.burns.2011.04.007","volume":"37","author":"C Haest","year":"2011","unstructured":"Haest C, Casaer MP, Daems A, De Vos B, Vermeersch E, Morren MA, et al. Measurement of itching: validation of the Leuven Itch Scale. Burns. 2011;37:939\u201350. \n                    https:\/\/doi.org\/10.1016\/j.burns.2011.04.007\n                    \n                  .","journal-title":"Burns"},{"key":"3362_CR18","first-page":"293","volume":"23","author":"SI Merkel","year":"1997","unstructured":"Merkel SI, Voepel-Lewis T, Shayevitz JR, Malviya S. The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr Nurs. 1997;23:293\u20137.","journal-title":"Pediatr Nurs"},{"key":"3362_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1553-2712.2009.00620.x","volume":"17","author":"G Garra","year":"2010","unstructured":"Garra G, Singer AJ, Taira BR, Chohan J, Cardoz H, Chisena E, et al. Validation of the Wong-Baker FACES Pain Rating Scale in pediatric emergency department patients. Acad Emerg Med. 2010;17:50\u20134. \n                    https:\/\/doi.org\/10.1111\/j.1553-2712.2009.00620.x\n                    \n                  .","journal-title":"Acad Emerg Med"},{"key":"3362_CR20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/wrr.12193","volume":"22","author":"C Blome","year":"2014","unstructured":"Blome C, Baade K, Debus ES, Price P, Augustin M. The \u201cWound-QoL\u201d: a short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. Wound Repair Regen. 2014;22:504\u201314. \n                    https:\/\/doi.org\/10.1111\/wrr.12193\n                    \n                  .","journal-title":"Wound Repair Regen"},{"key":"3362_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36. \n                    https:\/\/doi.org\/10.1186\/1477-7525-7-36\n                    \n                  .","journal-title":"Health Qual Life Outcomes"},{"key":"3362_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jaad.2010.01.047","volume":"66","author":"I Lara-Corrales","year":"2012","unstructured":"Lara-Corrales I, Parkin PC, Stephens D, Hamilton J, Koren G, Weinstein M, et al. The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: a feasibility trial. J Am Acad Dermatol. 2012;66:264\u201370. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2010.01.047\n                    \n                  .","journal-title":"J Am Acad Dermatol"},{"key":"3362_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.0006-341X.1999.00853.x","volume":"55","author":"L Cui","year":"1999","unstructured":"Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics. 1999;55:853\u20137.","journal-title":"Biometrics"},{"key":"3362_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/bjs.7030","volume":"97","author":"F Gottrup","year":"2010","unstructured":"Gottrup F, Apelqvist J. The challenge of using randomized trials in wound healing. Br J Surg. 2010;97:303\u20134. \n                    https:\/\/doi.org\/10.1002\/bjs.7030\n                    \n                  .","journal-title":"Br J Surg"},{"key":"3362_CR25","unstructured":"Keown A. Amicus Ends Lead Rare Disease Drug Program. PharmaLive; 2017. \n                    http:\/\/www.pharmalive.com\/amicus-dumps-lead-rare-disease-drug-after-phase-iii-trial-failure\/\n                    \n                  ."},{"key":"3362_CR26","doi-asserted-by":"publisher","first-page":"Abstract 219","DOI":"10.1016\/j.jid.2017.02.234","volume":"137","author":"D Solis","year":"2017","unstructured":"Solis D, Nazaroff J, Dutt-Singkh Y, Choi S, Barriga M, Bailey-Healy I, et al. Natural history of chronic wounds in patients with recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2017;137:Abstract 219.","journal-title":"J Invest Dermatol"},{"key":"3362_CR27","unstructured":"Food and Drug Administration. Epidermolysis bullosa: developing drugs for treatment of cutaneous manifestations guidance for industry. Silver Spring: Food and Drug Administration; 2018."},{"key":"3362_CR28","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jaad.2018.01.019","volume":"78","author":"V Wally","year":"2018","unstructured":"Wally V, Hovnanian A, Ly J, Buckova H, Brunner V, Lettner T, et al. Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2\/3 randomized, placebo-controlled, double-blind clinical trial. J Am Acad Dermatol. 2018;78:892\u2013901.e7. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2018.01.019\n                    \n                  .","journal-title":"J Am Acad Dermatol"},{"key":"3362_CR29","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1365-2133.2009.09347.x","volume":"161","author":"JW Frew","year":"2009","unstructured":"Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol. 2009;161:1323\u201330. \n                    https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09347.x\n                    \n                  .","journal-title":"Br J Dermatol"},{"key":"3362_CR30","unstructured":"Food and Drug Administration. Patient reported outcome measures: use in medical product development to support labeling claims. Silver Spring: Food and Drug Administration; 2009."},{"key":"3362_CR31","doi-asserted-by":"publisher","first-page":"A480","DOI":"10.1016\/j.jval.2012.08.1574","volume":"15","author":"M Mordin","year":"2012","unstructured":"Mordin M, Clark M, Doward L, Willian MK. Pediatric patient-reported outcomes assessment: a case study in epidermolysis bullosa. Value Health. 2012;15:A480\u20131.","journal-title":"Value Health"},{"key":"3362_CR32","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1365-4632.2010.04557.x","volume":"49","author":"SS Venugopal","year":"2010","unstructured":"Venugopal SS, Intong LR, Cohn HI, Mather-Hillon J, Murrell DF. Responsiveness of nonHerlitz junctional epidermolysis bullosa to topical gentian violet. Int J Dermatol. 2010;49:1282\u20135. \n                    https:\/\/doi.org\/10.1111\/j.1365-4632.2010.04557.x\n                    \n                  .","journal-title":"Int J Dermatol"},{"key":"3362_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1365-2230.2004.01428.x","volume":"29","author":"JD Fine","year":"2004","unstructured":"Fine JD, Johnson LB, Weiner M, Suchindran C. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol. 2004;29:122\u20137.","journal-title":"Clin Exp Dermatol"},{"key":"3362_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/pde.12391","volume":"32","author":"C Danial","year":"2015","unstructured":"Danial C, Adeduntan R, Gorell ES, Lucky AW, Paller AS, Bruckner A, et al. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol. 2015;32:53\u20139. \n                    https:\/\/doi.org\/10.1111\/pde.12391\n                    \n                  .","journal-title":"Pediatr Dermatol"},{"key":"3362_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12. \n                    https:\/\/doi.org\/10.1186\/1477-7525-2-12\n                    \n                  .","journal-title":"Health Qual Life Outcomes"},{"key":"3362_CR36","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"3362_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.12968\/jowc.2005.14.6.26792","volume":"14","author":"NK Rai","year":"2005","unstructured":"Rai NK, Suryabhan AM, Kumar M, Shukla VK, Tripathi K. Effect of glycaemic control on apoptosis in diabetic wounds. J Wound Care. 2005;14:277\u201381. \n                    https:\/\/doi.org\/10.12968\/jowc.2005.14.6.26792\n                    \n                  .","journal-title":"J Wound Care"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3362-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3362-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3362-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T23:28:51Z","timestamp":1591745331000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3362-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3362"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3362-z","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"assertion":[{"value":"17 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EASE is conducted in accordance with the principles of the Declaration of Helsinki. The trial has received institutional review board approval at all participating sites. All patients\/guardians provide written informed consent for all aspects of the trial (including collection of biological specimens) to the principal investigators before enrollment. Written approval was obtained from institutional review boards of the participating sites; any protocol amendments were signed off by the same bodies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have consent from the EASE study group and the sponsor for the publication of this paper. Publication is covered in the patient consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JSK: consultant for Amryt for trial design and is the international coordinating investigator of the study presented here. He participated in an Amryt advisory board meetingASB: consultant for Amryt, conducted the BEB-10 study, and participated in an Amryt advisory board meetingSL: consultant for Amryt Pharmaceuticals DACMS: paid employee of Amryt Pharmaceuticals DACCD: consultant for Amryt Pharmaceuticals DACAM: consultant for Amryt and participated in an Amryt advisory board meeting","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"350"}}